Another analysis showed that patients receiving antiplatelet agents other than aspirin, mainly ticlopidine hydrochloride, were at high risk of alteplase-induced HT [26], although the safety of combination therapy with alteplase and P2Y12 inhibitors other than clopidogrel sulfate has not been well reported. The gene discussed is P2RY12; the disease is hematocrit.